Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2947)	10/3/2013 1:09:01 PM
From: scaram(o)uche	1 Recommendation Recommended By quantman Respond to of 3202

>> “With our portfolio of JAK1 inhibitors, we’re well-positioned to potentially pursue development in chronic inflammatory conditions and oncology with separate molecules, as we did with our JAK1/JAK2 inhibitor program.” << This reflects either mega confidence/guts or mega crazies, and there's not much air between them. They're approaching companies and assuring them that 110 can compete with baricitinib.